Prenatal Genomics —
Training activity: 7

Details

Analyse, interpret and report the results of cell free DNA diagnosis, to include NIPD. Select appropriate reflex tests and prepare interpretive reports for a range prenatal cases

Type

Developmental training activity (DTA)

Evidence requirements

Evidence the activity has been undertaken by the trainee​.

Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.

An action plan to implement learning and/or to address skills or knowledge gaps identified.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

• Do you have a comprehensive understanding of the advanced applications of cfDNA analysis beyond screening, specifically regarding how NIPD is used for single-gene disorders or other specific genomic conditions?
• Are you fully aware of the technical challenges and limitations of NIPD—such as maternal cell contamination (MCC), allele drop-out, and mosaicism—and how these factors must be accounted for in a safe and high-quality service?
• How effectively can you identify when NIPD is the most appropriate testing strategy for a patient, and do you understand the criteria for selecting relevant reflex tests based on the findings?
• What specific insights do you hope to gain regarding the rationale for using NIPD in the prenatal pathway, and how do you anticipate this will enhance your ability to perform targeted molecular testing for familial variants?
• What aspects of interpreting NIPD data—particularly when results are discordant or inconclusive—are you interested in learning more about to ensure your clinical reports are clear and actionable?
• What preparatory steps have you taken, such as reviewing the current literature on NIPD applications or discussing the specific assays and conditions covered by your laboratory’s service with your training officer?
• How have you prepared to manage potential interpretation challenges, and have you planned how you will seek immediate advice or clarification if you encounter a complex or conclusive result?
• How do you feel about embarking on this activity, given the diagnostic nature of NIPD (as opposed to screening) and its direct implications for the pregnancy and the family?

In action

• What are the specific steps you are currently taking to analyse and interpret the results from cell free DNA (cfDNA) diagnosis, including Non-Invasive Prenatal Diagnosis (NIPD)? What specific targets or regions are you focusing on, and why (e.g., known familial mutations)?
• What key decisions are you making right now as you evaluate the presence or absence of the specific genetic variant(s) being tested for? For instance, how are you assessing the quality of the data and the confidence in the result? How are you deciding on the need for reflex testing (e.g., invasive testing for confirmation)?
• How effectively are your chosen methods allowing you to detect or exclude the specific genetic condition being investigated through NIPD?
• What challenges are you encountering in this moment, such as low levels of fetal DNA, ambiguous results, or technical issues with the assay?
• What can you learn from the data as it unfolds? Are there any unexpected findings or deviations from expected patterns based on the family history?
• How does this activity connect with your understanding of targeted molecular testing, allele-specific assays, and the advantages and limitations of NIPD compared to NIPT for screening?
• If your initial analysis yields an inconclusive or unexpected result, what alternative strategies could you employ? Could you review the laboratory workflow, consider alternative testing methodologies, or request further clinical information?
• Do you need to seek immediate clarification or advice on the interpretation of a complex NIPD result or the appropriate reflex testing strategy?
• Are you ensuring that your interpretation and reporting clearly convey the diagnostic nature of NIPD (when applicable) and the implications of the result for the pregnancy and family?

On action

• Begin by summarising the key findings from the cell-free DNA diagnosis (cfDNA-D), including non-invasive prenatal diagnosis (NIPD), results you analysed.
  • What specific diagnoses were being investigated or confirmed? What reflex tests were considered or performed following the cfDNA-D results?
  • What were the key considerations in preparing the interpretive reports for these cases?
• What skills or knowledge did you develop or improve in analysing and interpreting cfDNA-D/NIPD results, selecting reflex tests, and preparing interpretive reports?
  • Were there any unexpected challenges or successes during the activity?
  • What did you learn from these, such as the complexities of RhD typing by NIPD or interpreting discordant results?
• What areas for continued development have been identified as a result of this activity, such as a deeper understanding of the technical limitations of NIPD or the interpretation of complex NIPD results?
  • How can you apply the learning from this activity to your routine practice when dealing with cfDNA NIPD?
  • What actions will you now take to support the assimilation of what you have learned, such as reviewing the national guidelines for NIPD implementation?
  • What support or resources might you need to further develop in the areas identified through this reflection, such as case discussions focused on NIPD challenges?

Beyond action

• Have you revisited the experiences of analysing, interpreting, and reporting results for cell-free DNA (cfDNA) diagnosis, including non-invasive prenatal diagnosis (NIPD)? Compare your initial approach to selecting reflex tests following NIPD results with your current decision-making process. What refinements have you made?
• Review your reflections on cfDNA diagnosis within the context of the broader Prenatal Genomics module. What key learnings have emerged regarding the application of this technology in different prenatal scenarios?
• Have discussions with colleagues about the clinical utility and limitations of NIPD influenced your perspective?
• Recognise how this DTA has enhanced your specialist knowledge of prenatal genomics service delivery. How has your ability to integrate NIPD into appropriate testing strategies evolved?
• How have you applied your understanding of cfDNA diagnosis in subsequent prenatal cases, including those requiring reflex testing? Have you become more confident in explaining the implications of NIPD results to healthcare professionals?
• Define specific actions for continued development in the area of cfDNA diagnosis, such as staying abreast of new applications of NIPD and understanding its role in evolving prenatal testing pathways.

Relevant learning outcomes

#	Outcome
# 3	Outcome Apply appropriate testing strategies to patients with a family history of a genetic disorder.
# 5	Outcome Interpret genomic variants, including copy number changes and investigate the clinical significance of variants using bioinformatic tools using best practice guidelines.
# 6	Outcome Interpret and report prenatal genomic findings, including appropriate recommendations for patient management.